Join Medicilon at ELRIG Research & Innovation 2022 – for tomorrow's drug discovery

Medicilon welcomes you to join us at ELRIG RESEARCH & INNOVATION 2022.

DATE: 29-30 March 2022

LOCATION: THE KINGS CENTRE, OXFORD

Booth: 26

This year, 2022 ELRIG Research & Innovation conference will discuss how cutting edge science continues to be identified and explore how emerging technologies will enable this science to be translated into successful therapeutics. The four sessions will address different aspects of innovation across drug discovery and place an emphasis on both the digital age and novel modalities.

Omics technology innovations

Exciting advances in omics has transformed drug discovery. This session will focus on technologies that generate smart, dynamic and unbiased data.

The future of therapeutic genome engineering 

Over the last few years, the exuberant development of genome editing technologies has revolutionised drug discovery and targeted therapy of human diseases. This session will focus on most recent advances innovations in therapeutic genome engineering.

Drug discovery in the digital age
Networks of cross-discipline researchers are becoming increasingly armed with powerful virtual technologies at different stages of drug discovery and innovative tools for collaboration, this session will discuss the new innovations that will continue to drive drug discovery in the digital age. 

RNA therapeutics & RNA targets at the forefront   

Recent success with RNA-based vaccines has propelled RNA technologies to the forefront of drug discovery research. This session will focus on innovations in the field to highlight both the next wave of therapeutic RNA-based technologies alongside progress in modulating RNA targets to treat disease.

At Medicilon, chemistry and biology are ingrained in every project we undertake. Our medicinal chemistry team is capable of flexibly applying computer chemistry to assist compound design process. In the meantime, we apply advanced drug discovery technologies, including proteolysis-targeting chimera (PROTAC), antibody drug conjugation (ADC), etc. We are also proud of our rich experience in innovative design and patent strategies that complement our technologies. In addition, our responsive project management and effective communication help optimize our project delivery.

Our EU BD Vice President, Dr. Paul van Stralen, will be hosting the booth at the conference. Please feel free to visit him for detailed information on Medicilon’s integrated services. Join us at ELRIG Research & Innovation 2022 for a two-day journey into the insightful world of drug discovery and preclinical drug development.

Medicilon looks forward to meeting you.

#drugdiscovery